{"nct_id":"NCT01899742","title":"The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium","status":"COMPLETED","status_verified_date":"2018-01","start_date":"2014-09-15","start_date_type":"ACTUAL","primary_completion_date":"2015-07-22","primary_completion_date_type":"ACTUAL","completion_date":"2015-07-22","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GSK"]}